{"count":41,"next":"https://lda.gov/api/v1/filings/?client_name=Roivant&ordering=-dt_posted&page=2&page_size=25","previous":null,"results":[{"url":"https://lda.gov/api/v1/filings/8430a519-1366-4fa0-822b-3274ea78ce56/","filing_uuid":"8430a519-1366-4fa0-822b-3274ea78ce56","filing_type":"1TY","filing_type_display":"1st Quarter - Termination (No Activity)","filing_year":2022,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/8430a519-1366-4fa0-822b-3274ea78ce56/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Darin Gardner","dt_posted":"2022-04-19T17:10:15-04:00","termination_date":"2022-01-01","registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"2200 Pennsylvania Ave, NW","registrant_address_2":"Suite 600W","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20037","registrant":{"id":401004840,"url":"https://lda.gov/api/v1/registrants/401004840/","house_registrant_id":null,"name":"THE CONAFAY GROUP, LLC","description":"Life Sciences Consulting Firm","address_1":"1717 K St., NW","address_2":"Suite 900","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20006","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ERICA WOODWARD","contact_telephone":"+1 859-229-7237","dt_updated":"2026-07-30T09:45:36.196045-04:00"},"client":{"id":205173,"url":"https://lda.gov/api/v1/clients/205173/","client_id":443,"name":"ROIVANT SCIENCES, INC.","general_description":"Biotechnology Company","client_government_entity":false,"client_self_select":null,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-04-12"},"lobbying_activities":[],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/0cf21c1a-344a-419c-85cf-279dc574ce72/","filing_uuid":"0cf21c1a-344a-419c-85cf-279dc574ce72","filing_type":"Q4","filing_type_display":"4th Quarter - Report","filing_year":2021,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.gov/filings/public/filing/0cf21c1a-344a-419c-85cf-279dc574ce72/print/","filing_document_content_type":"text/html","income":"20000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Darin Gardner","dt_posted":"2022-01-14T17:02:39.990000-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"2200 Pennsylvania Ave, NW","registrant_address_2":"Suite 600W","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20037","registrant":{"id":401004840,"url":"https://lda.gov/api/v1/registrants/401004840/","house_registrant_id":null,"name":"THE CONAFAY GROUP, LLC","description":"Life Sciences Consulting Firm","address_1":"1717 K St., NW","address_2":"Suite 900","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20006","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ERICA WOODWARD","contact_telephone":"+1 859-229-7237","dt_updated":"2026-07-30T09:45:36.196045-04:00"},"client":{"id":205173,"url":"https://lda.gov/api/v1/clients/205173/","client_id":443,"name":"ROIVANT SCIENCES, INC.","general_description":"Biotechnology Company","client_government_entity":false,"client_self_select":null,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-04-12"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Support for medical/disease research.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64541,"prefix":null,"prefix_display":null,"first_name":"JULIE","nickname":null,"middle_name":"P.","last_name":"PAWELCZYK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":127340,"prefix":"mr","prefix_display":"MR.","first_name":"DARIN","nickname":null,"middle_name":"L","last_name":"GARDNER","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent Senator Tim Hutchinson; Research Assistant Senate HELP Committee; Chief of Staff Congresswoman Kay Granger","new":false}],"government_entities":[]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Support for medical/disease research.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64541,"prefix":null,"prefix_display":null,"first_name":"JULIE","nickname":null,"middle_name":"P.","last_name":"PAWELCZYK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":127340,"prefix":"mr","prefix_display":"MR.","first_name":"DARIN","nickname":null,"middle_name":"L","last_name":"GARDNER","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent Senator Tim Hutchinson; Research Assistant Senate HELP Committee; Chief of Staff Congresswoman Kay Granger","new":false}],"government_entities":[]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/744505ec-8dc3-4720-b2ff-2cdd9a757d3e/","filing_uuid":"744505ec-8dc3-4720-b2ff-2cdd9a757d3e","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2021,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/744505ec-8dc3-4720-b2ff-2cdd9a757d3e/print/","filing_document_content_type":"text/html","income":"20000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Darin Gardner","dt_posted":"2021-10-19T15:28:47.750000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"2200 Pennsylvania Ave, NW","registrant_address_2":"Suite 600W","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20037","registrant":{"id":401004840,"url":"https://lda.gov/api/v1/registrants/401004840/","house_registrant_id":null,"name":"THE CONAFAY GROUP, LLC","description":"Life Sciences Consulting Firm","address_1":"1717 K St., NW","address_2":"Suite 900","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20006","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ERICA WOODWARD","contact_telephone":"+1 859-229-7237","dt_updated":"2026-07-30T09:45:36.196045-04:00"},"client":{"id":205173,"url":"https://lda.gov/api/v1/clients/205173/","client_id":443,"name":"ROIVANT SCIENCES, INC.","general_description":"Biotechnology Company","client_government_entity":false,"client_self_select":null,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-04-12"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Support for medical/disease research.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":127340,"prefix":"mr","prefix_display":"MR.","first_name":"DARIN","nickname":null,"middle_name":"L","last_name":"GARDNER","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent Senator Tim Hutchinson; Research Assistant Senate HELP Committee; Chief of Staff Congresswoman Kay Granger","new":false},{"lobbyist":{"id":64541,"prefix":null,"prefix_display":null,"first_name":"JULIE","nickname":null,"middle_name":"P.","last_name":"PAWELCZYK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Support for medical/disease research.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":127340,"prefix":"mr","prefix_display":"MR.","first_name":"DARIN","nickname":null,"middle_name":"L","last_name":"GARDNER","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent Senator Tim Hutchinson; Research Assistant Senate HELP Committee; Chief of Staff Congresswoman Kay Granger","new":false},{"lobbyist":{"id":64541,"prefix":null,"prefix_display":null,"first_name":"JULIE","nickname":null,"middle_name":"P.","last_name":"PAWELCZYK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/af1582a6-e4d5-484a-abbd-ab9f2336bef4/","filing_uuid":"af1582a6-e4d5-484a-abbd-ab9f2336bef4","filing_type":"2TY","filing_type_display":"2nd Quarter - Termination (No Activity)","filing_year":2021,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/af1582a6-e4d5-484a-abbd-ab9f2336bef4/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Nicole Carelli","dt_posted":"2021-07-19T16:01:39.467000-04:00","termination_date":"2021-06-17","registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"901 K Street NW","registrant_address_2":"Suite 900","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":5153,"url":"https://lda.gov/api/v1/registrants/5153/","house_registrant_id":30873,"name":"BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ","description":"Law firm","address_1":"901 K Street NW","address_2":"Suite 900","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"DUANE HANECKOW","contact_telephone":"+1 202-508-3400","dt_updated":"2026-07-17T16:11:23.326015-04:00"},"client":{"id":209629,"url":"https://lda.gov/api/v1/clients/209629/","client_id":1006803,"name":"ROIVANT SCIENCES, INC.","general_description":"Biotechnology company","client_government_entity":false,"client_self_select":null,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2021-02-06"},"lobbying_activities":[],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/4c80cd72-74ea-4b66-b0e3-cf3753308df5/","filing_uuid":"4c80cd72-74ea-4b66-b0e3-cf3753308df5","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2021,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/4c80cd72-74ea-4b66-b0e3-cf3753308df5/print/","filing_document_content_type":"text/html","income":"20000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Darin Gardner","dt_posted":"2021-07-08T15:36:31.527000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"2200 Pennsylvania Ave, NW","registrant_address_2":"Suite 600W","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20037","registrant":{"id":401004840,"url":"https://lda.gov/api/v1/registrants/401004840/","house_registrant_id":null,"name":"THE CONAFAY GROUP, LLC","description":"Life Sciences Consulting Firm","address_1":"1717 K St., NW","address_2":"Suite 900","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20006","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ERICA WOODWARD","contact_telephone":"+1 859-229-7237","dt_updated":"2026-07-30T09:45:36.196045-04:00"},"client":{"id":205173,"url":"https://lda.gov/api/v1/clients/205173/","client_id":443,"name":"ROIVANT SCIENCES, INC.","general_description":"Biotechnology Company","client_government_entity":false,"client_self_select":null,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-04-12"},"lobbying_activities":[{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Support for medical/disease research.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64541,"prefix":null,"prefix_display":null,"first_name":"JULIE","nickname":null,"middle_name":"P.","last_name":"PAWELCZYK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":127340,"prefix":"mr","prefix_display":"MR.","first_name":"DARIN","nickname":null,"middle_name":"L","last_name":"GARDNER","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent Senator Tim Hutchinson; Research Assistant Senate HELP Committee; Chief of Staff Congresswoman Kay Granger","new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Support for medical/disease research.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":127340,"prefix":"mr","prefix_display":"MR.","first_name":"DARIN","nickname":null,"middle_name":"L","last_name":"GARDNER","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent Senator Tim Hutchinson; Research Assistant Senate HELP Committee; Chief of Staff Congresswoman Kay Granger","new":false},{"lobbyist":{"id":64541,"prefix":null,"prefix_display":null,"first_name":"JULIE","nickname":null,"middle_name":"P.","last_name":"PAWELCZYK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/3ff6376b-4a2a-4b5d-8a15-51ca68e91001/","filing_uuid":"3ff6376b-4a2a-4b5d-8a15-51ca68e91001","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2021,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/3ff6376b-4a2a-4b5d-8a15-51ca68e91001/print/","filing_document_content_type":"text/html","income":"50000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Nicole Carelli","dt_posted":"2021-04-20T10:45:02.593000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"901 K Street NW","registrant_address_2":"Suite 900","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":5153,"url":"https://lda.gov/api/v1/registrants/5153/","house_registrant_id":30873,"name":"BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ","description":"Law firm","address_1":"901 K Street NW","address_2":"Suite 900","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"DUANE HANECKOW","contact_telephone":"+1 202-508-3400","dt_updated":"2026-07-17T16:11:23.326015-04:00"},"client":{"id":209629,"url":"https://lda.gov/api/v1/clients/209629/","client_id":1006803,"name":"ROIVANT SCIENCES, INC.","general_description":"Biotechnology company","client_government_entity":false,"client_self_select":null,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2021-02-06"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to COVID-19 therapy development and approval","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":63731,"prefix":null,"prefix_display":null,"first_name":"THOMAS","nickname":null,"middle_name":null,"last_name":"DASCHLE","suffix":null,"suffix_display":null},"covered_position":"Former United States Senator","new":false}],"government_entities":[{"id":11,"name":"Executive Office of the President (EOP)"},{"id":139,"name":"Natl Institutes of Health (NIH)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/dad65f33-a9ef-4cfd-ac30-272fae10e0d2/","filing_uuid":"dad65f33-a9ef-4cfd-ac30-272fae10e0d2","filing_type":"RR","filing_type_display":"Registration","filing_year":2021,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/dad65f33-a9ef-4cfd-ac30-272fae10e0d2/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Nicole Carelli","dt_posted":"2021-04-19T15:37:09-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"901 K Street NW","registrant_address_2":"Suite 900","registrant_different_address":null,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":5153,"url":"https://lda.gov/api/v1/registrants/5153/","house_registrant_id":30873,"name":"BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ","description":"Law firm","address_1":"901 K Street NW","address_2":"Suite 900","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"DUANE HANECKOW","contact_telephone":"+1 202-508-3400","dt_updated":"2026-07-17T16:11:23.326015-04:00"},"client":{"id":209629,"url":"https://lda.gov/api/v1/clients/209629/","client_id":1006803,"name":"ROIVANT SCIENCES, INC.","general_description":"Biotechnology company","client_government_entity":false,"client_self_select":null,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2021-02-06"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to COVID-19 therapy development and approval.","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":63731,"prefix":null,"prefix_display":null,"first_name":"THOMAS","nickname":null,"middle_name":null,"last_name":"DASCHLE","suffix":null,"suffix_display":null},"covered_position":"Former United States Senator","new":true},{"lobbyist":{"id":143784,"prefix":"ms","prefix_display":"MS.","first_name":"TIFFANI","nickname":null,"middle_name":"VIVIENNE","last_name":"WILLIAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/6b91f2d1-f77a-4962-b592-c36f164cbd10/","filing_uuid":"6b91f2d1-f77a-4962-b592-c36f164cbd10","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2021,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/6b91f2d1-f77a-4962-b592-c36f164cbd10/print/","filing_document_content_type":"text/html","income":"20000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Darin Gardner","dt_posted":"2021-04-15T11:45:59.840000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"2200 Pennsylvania Ave, NW","registrant_address_2":"Suite 600W","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20037","registrant":{"id":401004840,"url":"https://lda.gov/api/v1/registrants/401004840/","house_registrant_id":null,"name":"THE CONAFAY GROUP, LLC","description":"Life Sciences Consulting Firm","address_1":"1717 K St., NW","address_2":"Suite 900","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20006","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ERICA WOODWARD","contact_telephone":"+1 859-229-7237","dt_updated":"2026-07-30T09:45:36.196045-04:00"},"client":{"id":205173,"url":"https://lda.gov/api/v1/clients/205173/","client_id":443,"name":"ROIVANT SCIENCES, INC.","general_description":"Biotechnology Company","client_government_entity":false,"client_self_select":null,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-04-12"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Support for medical/disease research.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":127340,"prefix":"mr","prefix_display":"MR.","first_name":"DARIN","nickname":null,"middle_name":"L","last_name":"GARDNER","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent Senator Tim Hutchinson; Research Assistant Senate HELP Committee; Chief of Staff Congresswoman Kay Granger","new":false},{"lobbyist":{"id":64541,"prefix":null,"prefix_display":null,"first_name":"JULIE","nickname":null,"middle_name":"P.","last_name":"PAWELCZYK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Support for medical/disease research.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":127340,"prefix":"mr","prefix_display":"MR.","first_name":"DARIN","nickname":null,"middle_name":"L","last_name":"GARDNER","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent Senator Tim Hutchinson; Research Assistant Senate HELP Committee; Chief of Staff Congresswoman Kay Granger","new":false},{"lobbyist":{"id":64541,"prefix":null,"prefix_display":null,"first_name":"JULIE","nickname":null,"middle_name":"P.","last_name":"PAWELCZYK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/c5bf68f3-8ff6-441d-8d60-4667c8fc45c8/","filing_uuid":"c5bf68f3-8ff6-441d-8d60-4667c8fc45c8","filing_type":"Q4","filing_type_display":"4th Quarter - Report","filing_year":2020,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.gov/filings/public/filing/c5bf68f3-8ff6-441d-8d60-4667c8fc45c8/print/","filing_document_content_type":"text/html","income":"20000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Darin Gardner","dt_posted":"2021-01-19T17:35:47.780000-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"2200 Pennsylvania Ave, NW","registrant_address_2":"Suite 600W","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20037","registrant":{"id":401004840,"url":"https://lda.gov/api/v1/registrants/401004840/","house_registrant_id":null,"name":"THE CONAFAY GROUP, LLC","description":"Life Sciences Consulting Firm","address_1":"1717 K St., NW","address_2":"Suite 900","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20006","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ERICA WOODWARD","contact_telephone":"+1 859-229-7237","dt_updated":"2026-07-30T09:45:36.196045-04:00"},"client":{"id":205173,"url":"https://lda.gov/api/v1/clients/205173/","client_id":443,"name":"ROIVANT SCIENCES, INC.","general_description":"Biotechnology Company","client_government_entity":false,"client_self_select":null,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-04-12"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Support for medical/disease research.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":127340,"prefix":"mr","prefix_display":"MR.","first_name":"DARIN","nickname":null,"middle_name":"L","last_name":"GARDNER","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent Senator Tim Hutchinson; Research Assistant Senate HELP Committee; Chief of Staff Congresswoman Kay Granger","new":false},{"lobbyist":{"id":64541,"prefix":null,"prefix_display":null,"first_name":"JULIE","nickname":null,"middle_name":"P.","last_name":"PAWELCZYK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Support for medical/disease research.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":127340,"prefix":"mr","prefix_display":"MR.","first_name":"DARIN","nickname":null,"middle_name":"L","last_name":"GARDNER","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent Senator Tim Hutchinson; Research Assistant Senate HELP Committee; Chief of Staff Congresswoman Kay Granger","new":false},{"lobbyist":{"id":64541,"prefix":null,"prefix_display":null,"first_name":"JULIE","nickname":null,"middle_name":"P.","last_name":"PAWELCZYK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/336ab40c-3fc8-4301-96f7-74e050e1e2ee/","filing_uuid":"336ab40c-3fc8-4301-96f7-74e050e1e2ee","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2020,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/336ab40c-3fc8-4301-96f7-74e050e1e2ee/print/","filing_document_content_type":"text/html","income":"20000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Darin Gardner","dt_posted":"2020-10-16T18:10:55.877000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"2200 Pennsylvania Ave, NW","registrant_address_2":"Suite 600W","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20037","registrant":{"id":401004840,"url":"https://lda.gov/api/v1/registrants/401004840/","house_registrant_id":null,"name":"THE CONAFAY GROUP, LLC","description":"Life Sciences Consulting Firm","address_1":"1717 K St., NW","address_2":"Suite 900","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20006","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ERICA WOODWARD","contact_telephone":"+1 859-229-7237","dt_updated":"2026-07-30T09:45:36.196045-04:00"},"client":{"id":205173,"url":"https://lda.gov/api/v1/clients/205173/","client_id":443,"name":"ROIVANT SCIENCES, INC.","general_description":"Biotechnology Company","client_government_entity":false,"client_self_select":null,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-04-12"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Support for medical/disease research.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64541,"prefix":null,"prefix_display":null,"first_name":"JULIE","nickname":null,"middle_name":"P.","last_name":"PAWELCZYK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":127340,"prefix":"mr","prefix_display":"MR.","first_name":"DARIN","nickname":null,"middle_name":"L","last_name":"GARDNER","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent Senator Tim Hutchinson; Research Assistant Senate HELP Committee; Chief of Staff Congresswoman Kay Granger","new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Support for medical/disease research.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":127340,"prefix":"mr","prefix_display":"MR.","first_name":"DARIN","nickname":null,"middle_name":"L","last_name":"GARDNER","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent Senator Tim Hutchinson; Research Assistant Senate HELP Committee; Chief of Staff Congresswoman Kay Granger","new":false},{"lobbyist":{"id":64541,"prefix":null,"prefix_display":null,"first_name":"JULIE","nickname":null,"middle_name":"P.","last_name":"PAWELCZYK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/7b158ace-6164-4273-86dd-b19de6a13526/","filing_uuid":"7b158ace-6164-4273-86dd-b19de6a13526","filing_type":"2T","filing_type_display":"2nd Quarter - Termination","filing_year":2020,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/7b158ace-6164-4273-86dd-b19de6a13526/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Bryant Hall, President","dt_posted":"2020-07-20T17:32:13.867000-04:00","termination_date":"2020-05-31","registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1300 Connecticut Avenue, NW","registrant_address_2":"Suite 600","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20036","registrant":{"id":400712135,"url":"https://lda.gov/api/v1/registrants/400712135/","house_registrant_id":null,"name":"TIBER CREEK HEALTH STRATEGIES, INC.","description":"Government Relations.","address_1":"750 9th Street NW","address_2":"Suite 501","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JONATHON JONES","contact_telephone":"+1 202-775-8116","dt_updated":"2026-07-20T13:08:01.259800-04:00"},"client":{"id":194559,"url":"https://lda.gov/api/v1/clients/194559/","client_id":214,"name":"PECK MADIGAN JONES (ON BEHALF OF ROIVANT SCIENCES, INC.)","general_description":"Biopharmaceutical drug development.","client_government_entity":false,"client_self_select":null,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-04-18"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Development of therapeutics for COVID-19 and other respiratory conditions","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":54797,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"BRYANT","last_name":"HALL","suffix":"ii","suffix_display":"II"},"covered_position":null,"new":false}],"government_entities":[{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Development of therapeutics for COVID-19 and other respiratory conditions","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":54797,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"BRYANT","last_name":"HALL","suffix":"ii","suffix_display":"II"},"covered_position":null,"new":false}],"government_entities":[{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[{"name":"ROIVANT SCIENCES LTD.","contribution":"0.00","ownership_percentage":"100.00","address":"Clarendon House - 2 Church Street","city":"Hamilton","state":null,"state_display":null,"country":"BM","country_display":"Bermuda","ppb_city":"London","ppb_state":null,"ppb_state_display":null,"ppb_country":"GB","ppb_country_display":"United Kingdom"},{"name":"ROIVANT SCIENCES HOLDINGS LTD.","contribution":"0.00","ownership_percentage":"100.00","address":"11-12 St. James's Square, Suite 1, 3rd Floor","city":"London","state":null,"state_display":null,"country":"GB","country_display":"United Kingdom","ppb_city":"London","ppb_state":null,"ppb_state_display":null,"ppb_country":"GB","ppb_country_display":"United Kingdom"},{"name":"ROIVANT SCIENCES GMBH","contribution":"0.00","ownership_percentage":"0.00","address":"Viaduktstrasse 8 - 4051","city":"Basel","state":null,"state_display":null,"country":"CH","country_display":"Switzerland","ppb_city":"Basel","ppb_state":null,"ppb_state_display":null,"ppb_country":"CH","ppb_country_display":"Switzerland"}],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/8dcd8cd1-4965-42ad-9b24-aa83354cdd48/","filing_uuid":"8dcd8cd1-4965-42ad-9b24-aa83354cdd48","filing_type":"2T","filing_type_display":"2nd Quarter - Termination","filing_year":2020,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/8dcd8cd1-4965-42ad-9b24-aa83354cdd48/print/","filing_document_content_type":"text/html","income":"20000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Jeffrey J. Peck, Partner","dt_posted":"2020-07-20T15:22:41.930000-04:00","termination_date":"2020-05-31","registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1300 CONNECTICUT AVENUE, NW","registrant_address_2":"Suite 600","registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20036","registrant":{"id":20744,"url":"https://lda.gov/api/v1/registrants/20744/","house_registrant_id":31587,"name":"TIBER CREEK GROUP","description":"Government Relations.","address_1":"750 9th Street NW","address_2":"Suite 501","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"GRACE BAUM","contact_telephone":"+1 202-381-6896","dt_updated":"2026-07-20T13:07:00.819992-04:00"},"client":{"id":127265,"url":"https://lda.gov/api/v1/clients/127265/","client_id":1006168,"name":"ROIVANT SCIENCES, INC.","general_description":"Biopharmaceutical drug development.","client_government_entity":false,"client_self_select":null,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-04-18"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Development of therapeutics for COVID-19 and other respiratory conditions","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":65014,"prefix":null,"prefix_display":null,"first_name":"JAMES","nickname":null,"middle_name":null,"last_name":"HEIMBACH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":53494,"prefix":null,"prefix_display":null,"first_name":"ANDREW","nickname":null,"middle_name":null,"last_name":"MCKECHNIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":26450,"prefix":null,"prefix_display":null,"first_name":"JONATHON","nickname":null,"middle_name":null,"last_name":"JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":47178,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":"MICHAEL","last_name":"GONZALEZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":58384,"prefix":"mr","prefix_display":"MR.","first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"SHAPIRO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61401,"prefix":null,"prefix_display":null,"first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69921,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"LEFFINGWELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Development of therapeutics for COVID-19 and other respiratory conditions","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":65014,"prefix":null,"prefix_display":null,"first_name":"JAMES","nickname":null,"middle_name":null,"last_name":"HEIMBACH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":53494,"prefix":null,"prefix_display":null,"first_name":"ANDREW","nickname":null,"middle_name":null,"last_name":"MCKECHNIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":26450,"prefix":null,"prefix_display":null,"first_name":"JONATHON","nickname":null,"middle_name":null,"last_name":"JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":47178,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":"MICHAEL","last_name":"GONZALEZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":58384,"prefix":"mr","prefix_display":"MR.","first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"SHAPIRO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61401,"prefix":null,"prefix_display":null,"first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69921,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"LEFFINGWELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[{"name":"ROIVANT SCIENCES LTD.","contribution":"0.00","ownership_percentage":"100.00","address":"Clarendon House - 2 Church Street","city":"Hamilton","state":null,"state_display":null,"country":"BM","country_display":"Bermuda","ppb_city":"London","ppb_state":null,"ppb_state_display":null,"ppb_country":"GB","ppb_country_display":"United Kingdom"},{"name":"ROIVANT SCIENCES HOLDINGS LTD.","contribution":"0.00","ownership_percentage":"100.00","address":"11-12 St. James's Square, Suite 1, 3rd Floor","city":"London","state":null,"state_display":null,"country":"GB","country_display":"United Kingdom","ppb_city":"London","ppb_state":null,"ppb_state_display":null,"ppb_country":"GB","ppb_country_display":"United Kingdom"},{"name":"ROIVANT SCIENCES GMBH","contribution":"0.00","ownership_percentage":"0.00","address":"Viaduktstrasse 8 - 4051","city":"Basel","state":null,"state_display":null,"country":"CH","country_display":"Switzerland","ppb_city":"Basel","ppb_state":null,"ppb_state_display":null,"ppb_country":"CH","ppb_country_display":"Switzerland"}],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/77f843f4-de38-4b40-a024-95101c8178d5/","filing_uuid":"77f843f4-de38-4b40-a024-95101c8178d5","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2020,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/77f843f4-de38-4b40-a024-95101c8178d5/print/","filing_document_content_type":"text/html","income":"20000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Darin Gardner","dt_posted":"2020-07-17T15:41:48.510000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"2200 Pennsylvania Ave, NW","registrant_address_2":"Suite 600W","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20037","registrant":{"id":401004840,"url":"https://lda.gov/api/v1/registrants/401004840/","house_registrant_id":null,"name":"THE CONAFAY GROUP, LLC","description":"Life Sciences Consulting Firm","address_1":"1717 K St., NW","address_2":"Suite 900","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20006","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ERICA WOODWARD","contact_telephone":"+1 859-229-7237","dt_updated":"2026-07-30T09:45:36.196045-04:00"},"client":{"id":205173,"url":"https://lda.gov/api/v1/clients/205173/","client_id":443,"name":"ROIVANT SCIENCES, INC.","general_description":"Biotechnology Company","client_government_entity":false,"client_self_select":null,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-04-12"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Support for medical/disease research.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":127340,"prefix":"mr","prefix_display":"MR.","first_name":"DARIN","nickname":null,"middle_name":"L","last_name":"GARDNER","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent Senator Tim Hutchinson; Research Assistant Senate HELP Committee; Chief of Staff Congresswoman Kay Granger","new":false},{"lobbyist":{"id":64541,"prefix":null,"prefix_display":null,"first_name":"JULIE","nickname":null,"middle_name":"P.","last_name":"PAWELCZYK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Support for medical/disease research.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":127340,"prefix":"mr","prefix_display":"MR.","first_name":"DARIN","nickname":null,"middle_name":"L","last_name":"GARDNER","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent Senator Tim Hutchinson; Research Assistant Senate HELP Committee; Chief of Staff Congresswoman Kay Granger","new":false},{"lobbyist":{"id":64541,"prefix":null,"prefix_display":null,"first_name":"JULIE","nickname":null,"middle_name":"P.","last_name":"PAWELCZYK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[{"name":"ROIVANT SCIENCES LTD","contribution":"0.00","ownership_percentage":"100.00","address":"Clarendon House - 2 Church St","city":"Hamilton","state":null,"state_display":null,"country":"BM","country_display":"Bermuda","ppb_city":"London","ppb_state":null,"ppb_state_display":null,"ppb_country":"GB","ppb_country_display":"United Kingdom"},{"name":"ROIVANT SCIENCES HOLDINGS LTD","contribution":"0.00","ownership_percentage":"100.00","address":"11-12 St James's Square, Suite 1, 3rd Floor","city":"London","state":null,"state_display":null,"country":"GB","country_display":"United Kingdom","ppb_city":"London","ppb_state":null,"ppb_state_display":null,"ppb_country":"GB","ppb_country_display":"United Kingdom"},{"name":"ROIVANT SCIENCES GMBH","contribution":"0.00","ownership_percentage":"0.00","address":"Viadukstrasse 8-4051","city":"Basel","state":null,"state_display":null,"country":"CH","country_display":"Switzerland","ppb_city":"Basel","ppb_state":null,"ppb_state_display":null,"ppb_country":"CH","ppb_country_display":"Switzerland"}],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/05a93485-14af-4e6e-b33f-85880ed0a347/","filing_uuid":"05a93485-14af-4e6e-b33f-85880ed0a347","filing_type":"RR","filing_type_display":"Registration","filing_year":2020,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/05a93485-14af-4e6e-b33f-85880ed0a347/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Darin Gardner","dt_posted":"2020-04-24T17:56:03-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"2200 Pennsylvania Ave, NW","registrant_address_2":"Suite 600W","registrant_different_address":null,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20037","registrant":{"id":401004840,"url":"https://lda.gov/api/v1/registrants/401004840/","house_registrant_id":null,"name":"THE CONAFAY GROUP, LLC","description":"Life Sciences Consulting Firm","address_1":"1717 K St., NW","address_2":"Suite 900","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20006","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ERICA WOODWARD","contact_telephone":"+1 859-229-7237","dt_updated":"2026-07-30T09:45:36.196045-04:00"},"client":{"id":205173,"url":"https://lda.gov/api/v1/clients/205173/","client_id":443,"name":"ROIVANT SCIENCES, INC.","general_description":"Biotechnology Company","client_government_entity":false,"client_self_select":null,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-04-12"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Seek support for research and development funding.","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":127340,"prefix":"mr","prefix_display":"MR.","first_name":"DARIN","nickname":null,"middle_name":"L","last_name":"GARDNER","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent, Senator Tim Hutchinson; Research Assistant, Senate HELP Committee; Chief of Staff, Congresswoman Kay Granger","new":true}],"government_entities":[]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Seek support for research and development funding.","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":127340,"prefix":"mr","prefix_display":"MR.","first_name":"DARIN","nickname":null,"middle_name":"L","last_name":"GARDNER","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent, Senator Tim Hutchinson; Research Assistant, Senate HELP Committee; Chief of Staff, Congresswoman Kay Granger","new":true}],"government_entities":[]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/1ccef18a-643e-42bf-a228-62b8520dcb7a/","filing_uuid":"1ccef18a-643e-42bf-a228-62b8520dcb7a","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2020,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/1ccef18a-643e-42bf-a228-62b8520dcb7a/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Bryant Hall, President","dt_posted":"2020-04-20T18:35:45.273000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1300 Connecticut Avenue, NW","registrant_address_2":"Suite 600","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20036","registrant":{"id":400712135,"url":"https://lda.gov/api/v1/registrants/400712135/","house_registrant_id":null,"name":"TIBER CREEK HEALTH STRATEGIES, INC.","description":"Government Relations.","address_1":"750 9th Street NW","address_2":"Suite 501","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JONATHON JONES","contact_telephone":"+1 202-775-8116","dt_updated":"2026-07-20T13:08:01.259800-04:00"},"client":{"id":194559,"url":"https://lda.gov/api/v1/clients/194559/","client_id":214,"name":"PECK MADIGAN JONES (ON BEHALF OF ROIVANT SCIENCES, INC.)","general_description":"Biopharmaceutical drug development.","client_government_entity":false,"client_self_select":null,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-04-18"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to the development of gene therapies","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":54797,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"BRYANT","last_name":"HALL","suffix":"ii","suffix_display":"II"},"covered_position":null,"new":false}],"government_entities":[{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Issues related to the development of gene therapies","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":54797,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"BRYANT","last_name":"HALL","suffix":"ii","suffix_display":"II"},"covered_position":null,"new":false}],"government_entities":[{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[{"name":"ROIVANT SCIENCES LTD.","contribution":"0.00","ownership_percentage":"100.00","address":"Clarendon House - 2 Church Street","city":"Hamilton","state":null,"state_display":null,"country":"BM","country_display":"Bermuda","ppb_city":"London","ppb_state":null,"ppb_state_display":null,"ppb_country":"GB","ppb_country_display":"United Kingdom"},{"name":"ROIVANT SCIENCES HOLDINGS LTD.","contribution":"0.00","ownership_percentage":"100.00","address":"11-12 St. James's Square, Suite 1, 3rd Floor","city":"London","state":null,"state_display":null,"country":"GB","country_display":"United Kingdom","ppb_city":"London","ppb_state":null,"ppb_state_display":null,"ppb_country":"GB","ppb_country_display":"United Kingdom"},{"name":"ROIVANT SCIENCES GMBH","contribution":"0.00","ownership_percentage":"0.00","address":"Viaduktstrasse 8 - 4051","city":"Basel","state":null,"state_display":null,"country":"CH","country_display":"Switzerland","ppb_city":"Basel","ppb_state":null,"ppb_state_display":null,"ppb_country":"CH","ppb_country_display":"Switzerland"}],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/2d20ba6f-feab-462d-8344-15e32ed09836/","filing_uuid":"2d20ba6f-feab-462d-8344-15e32ed09836","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2020,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/2d20ba6f-feab-462d-8344-15e32ed09836/print/","filing_document_content_type":"text/html","income":"50000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Jeffrey J. Peck, Partner","dt_posted":"2020-04-20T17:11:07.800000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1300 CONNECTICUT AVENUE, NW","registrant_address_2":"Suite 600","registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20036","registrant":{"id":20744,"url":"https://lda.gov/api/v1/registrants/20744/","house_registrant_id":31587,"name":"TIBER CREEK GROUP","description":"Government Relations.","address_1":"750 9th Street NW","address_2":"Suite 501","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"GRACE BAUM","contact_telephone":"+1 202-381-6896","dt_updated":"2026-07-20T13:07:00.819992-04:00"},"client":{"id":127265,"url":"https://lda.gov/api/v1/clients/127265/","client_id":1006168,"name":"ROIVANT SCIENCES, INC.","general_description":"Biopharmaceutical drug development.","client_government_entity":false,"client_self_select":null,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-04-18"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Development of gene therapies","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":65014,"prefix":null,"prefix_display":null,"first_name":"JAMES","nickname":null,"middle_name":null,"last_name":"HEIMBACH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":53494,"prefix":null,"prefix_display":null,"first_name":"ANDREW","nickname":null,"middle_name":null,"last_name":"MCKECHNIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":26450,"prefix":null,"prefix_display":null,"first_name":"JONATHON","nickname":null,"middle_name":null,"last_name":"JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":47178,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":"MICHAEL","last_name":"GONZALEZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":58384,"prefix":"mr","prefix_display":"MR.","first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"SHAPIRO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61401,"prefix":null,"prefix_display":null,"first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69921,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"LEFFINGWELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TEC","general_issue_code_display":"Telecommunications","description":"Issues pertaining to telemedicine and implementation of Special Registration rule. Implementation of SUPPORT for Patients and Communities Act (Public Law No: 115-271).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":65014,"prefix":null,"prefix_display":null,"first_name":"JAMES","nickname":null,"middle_name":null,"last_name":"HEIMBACH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":53494,"prefix":null,"prefix_display":null,"first_name":"ANDREW","nickname":null,"middle_name":null,"last_name":"MCKECHNIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":26450,"prefix":null,"prefix_display":null,"first_name":"JONATHON","nickname":null,"middle_name":null,"last_name":"JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":58384,"prefix":"mr","prefix_display":"MR.","first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"SHAPIRO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":47178,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":"MICHAEL","last_name":"GONZALEZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61401,"prefix":null,"prefix_display":null,"first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69921,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"LEFFINGWELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Development of gene therapies and telemedicine","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":65014,"prefix":null,"prefix_display":null,"first_name":"JAMES","nickname":null,"middle_name":null,"last_name":"HEIMBACH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":53494,"prefix":null,"prefix_display":null,"first_name":"ANDREW","nickname":null,"middle_name":null,"last_name":"MCKECHNIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":26450,"prefix":null,"prefix_display":null,"first_name":"JONATHON","nickname":null,"middle_name":null,"last_name":"JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":47178,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":"MICHAEL","last_name":"GONZALEZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":58384,"prefix":"mr","prefix_display":"MR.","first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"SHAPIRO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61401,"prefix":null,"prefix_display":null,"first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69921,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"LEFFINGWELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[{"name":"ROIVANT SCIENCES LTD.","contribution":"0.00","ownership_percentage":"100.00","address":"Clarendon House - 2 Church Street","city":"Hamilton","state":null,"state_display":null,"country":"BM","country_display":"Bermuda","ppb_city":"London","ppb_state":null,"ppb_state_display":null,"ppb_country":"GB","ppb_country_display":"United Kingdom"},{"name":"ROIVANT SCIENCES HOLDINGS LTD.","contribution":"0.00","ownership_percentage":"100.00","address":"11-12 St. James's Square, Suite 1, 3rd Floor","city":"London","state":null,"state_display":null,"country":"GB","country_display":"United Kingdom","ppb_city":"London","ppb_state":null,"ppb_state_display":null,"ppb_country":"GB","ppb_country_display":"United Kingdom"},{"name":"ROIVANT SCIENCES GMBH","contribution":"0.00","ownership_percentage":"0.00","address":"Viaduktstrasse 8 - 4051","city":"Basel","state":null,"state_display":null,"country":"CH","country_display":"Switzerland","ppb_city":"Basel","ppb_state":null,"ppb_state_display":null,"ppb_country":"CH","ppb_country_display":"Switzerland"}],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/148b87ed-83d7-4885-a782-0351ecfb3371/","filing_uuid":"148b87ed-83d7-4885-a782-0351ecfb3371","filing_type":"Q4","filing_type_display":"4th Quarter - Report","filing_year":2019,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.gov/filings/public/filing/148b87ed-83d7-4885-a782-0351ecfb3371/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Bryant Hall, President","dt_posted":"2020-01-21T18:04:16.087000-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1300 Connecticut Avenue, NW","registrant_address_2":"Suite 600","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20036","registrant":{"id":400712135,"url":"https://lda.gov/api/v1/registrants/400712135/","house_registrant_id":null,"name":"TIBER CREEK HEALTH STRATEGIES, INC.","description":"Government Relations.","address_1":"750 9th Street NW","address_2":"Suite 501","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JONATHON JONES","contact_telephone":"+1 202-775-8116","dt_updated":"2026-07-20T13:08:01.259800-04:00"},"client":{"id":194559,"url":"https://lda.gov/api/v1/clients/194559/","client_id":214,"name":"PECK MADIGAN JONES (ON BEHALF OF ROIVANT SCIENCES, INC.)","general_description":"Biopharmaceutical drug development.","client_government_entity":false,"client_self_select":null,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-04-18"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to the development of gene therapies","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":54797,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"BRYANT","last_name":"HALL","suffix":"ii","suffix_display":"II"},"covered_position":null,"new":false}],"government_entities":[{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Issues related to the development of gene therapies","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":54797,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"BRYANT","last_name":"HALL","suffix":"ii","suffix_display":"II"},"covered_position":null,"new":false}],"government_entities":[{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[{"name":"ROIVANT SCIENCES LTD.","contribution":"0.00","ownership_percentage":"100.00","address":"Clarendon House - 2 Church Street","city":"Hamilton","state":null,"state_display":null,"country":"BM","country_display":"Bermuda","ppb_city":"London","ppb_state":null,"ppb_state_display":null,"ppb_country":"GB","ppb_country_display":"United Kingdom"},{"name":"ROIVANT SCIENCES HOLDINGS LTD.","contribution":"0.00","ownership_percentage":"100.00","address":"11-12 St. James's Square, Suite 1, 3rd Floor","city":"London","state":null,"state_display":null,"country":"GB","country_display":"United Kingdom","ppb_city":"London","ppb_state":null,"ppb_state_display":null,"ppb_country":"GB","ppb_country_display":"United Kingdom"},{"name":"ROIVANT SCIENCES GMBH","contribution":"0.00","ownership_percentage":"0.00","address":"Viaduktstrasse 8 - 4051","city":"Basel","state":null,"state_display":null,"country":"CH","country_display":"Switzerland","ppb_city":"Basel","ppb_state":null,"ppb_state_display":null,"ppb_country":"CH","ppb_country_display":"Switzerland"}],"affiliated_organizations":[{"name":"ROIVANT SCIENCES, INC.","url":null,"address_1":"320 West 37th Street","address_2":null,"address_3":null,"address_4":null,"city":"New York","state":"NY","state_display":"New York","zip":"10018","country":"US","country_display":"United States of America","ppb_city":null,"ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America"}]},{"url":"https://lda.gov/api/v1/filings/71ff499d-520a-4670-9484-819bcdb6d44e/","filing_uuid":"71ff499d-520a-4670-9484-819bcdb6d44e","filing_type":"Q4","filing_type_display":"4th Quarter - Report","filing_year":2019,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.gov/filings/public/filing/71ff499d-520a-4670-9484-819bcdb6d44e/print/","filing_document_content_type":"text/html","income":"70000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Jeffrey J. Peck, Partner","dt_posted":"2020-01-21T17:38:23.027000-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1300 CONNECTICUT AVENUE, NW","registrant_address_2":"Suite 600","registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20036","registrant":{"id":20744,"url":"https://lda.gov/api/v1/registrants/20744/","house_registrant_id":31587,"name":"TIBER CREEK GROUP","description":"Government Relations.","address_1":"750 9th Street NW","address_2":"Suite 501","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"GRACE BAUM","contact_telephone":"+1 202-381-6896","dt_updated":"2026-07-20T13:07:00.819992-04:00"},"client":{"id":127265,"url":"https://lda.gov/api/v1/clients/127265/","client_id":1006168,"name":"ROIVANT SCIENCES, INC.","general_description":"Biopharmaceutical drug development.","client_government_entity":false,"client_self_select":null,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-04-18"},"lobbying_activities":[{"general_issue_code":"TEC","general_issue_code_display":"Telecommunications","description":"Issues pertaining to telemedicine and implementation of Special Registration rule. Implementation of SUPPORT for Patients and Communities Act (Public Law No: 115-271).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":65014,"prefix":null,"prefix_display":null,"first_name":"JAMES","nickname":null,"middle_name":null,"last_name":"HEIMBACH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":53494,"prefix":null,"prefix_display":null,"first_name":"ANDREW","nickname":null,"middle_name":null,"last_name":"MCKECHNIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":26450,"prefix":null,"prefix_display":null,"first_name":"JONATHON","nickname":null,"middle_name":null,"last_name":"JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":58384,"prefix":"mr","prefix_display":"MR.","first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"SHAPIRO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":47178,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":"MICHAEL","last_name":"GONZALEZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61401,"prefix":null,"prefix_display":null,"first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69921,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"LEFFINGWELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Treatment of diabetes, development of gene therapies, telemedicine","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":65014,"prefix":null,"prefix_display":null,"first_name":"JAMES","nickname":null,"middle_name":null,"last_name":"HEIMBACH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":53494,"prefix":null,"prefix_display":null,"first_name":"ANDREW","nickname":null,"middle_name":null,"last_name":"MCKECHNIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":26450,"prefix":null,"prefix_display":null,"first_name":"JONATHON","nickname":null,"middle_name":null,"last_name":"JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":47178,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":"MICHAEL","last_name":"GONZALEZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":58384,"prefix":"mr","prefix_display":"MR.","first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"SHAPIRO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61401,"prefix":null,"prefix_display":null,"first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69921,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"LEFFINGWELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Treatment of diabetes, development of gene therapies","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":65014,"prefix":null,"prefix_display":null,"first_name":"JAMES","nickname":null,"middle_name":null,"last_name":"HEIMBACH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":53494,"prefix":null,"prefix_display":null,"first_name":"ANDREW","nickname":null,"middle_name":null,"last_name":"MCKECHNIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":26450,"prefix":null,"prefix_display":null,"first_name":"JONATHON","nickname":null,"middle_name":null,"last_name":"JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":47178,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":"MICHAEL","last_name":"GONZALEZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":58384,"prefix":"mr","prefix_display":"MR.","first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"SHAPIRO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61401,"prefix":null,"prefix_display":null,"first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69921,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"LEFFINGWELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[{"name":"ROIVANT SCIENCES LTD.","contribution":"0.00","ownership_percentage":"100.00","address":"Clarendon House - 2 Church Street","city":"Hamilton","state":null,"state_display":null,"country":"BM","country_display":"Bermuda","ppb_city":"London","ppb_state":null,"ppb_state_display":null,"ppb_country":"GB","ppb_country_display":"United Kingdom"},{"name":"ROIVANT SCIENCES HOLDINGS LTD.","contribution":"0.00","ownership_percentage":"100.00","address":"11-12 St. James's Square, Suite 1, 3rd Floor","city":"London","state":null,"state_display":null,"country":"GB","country_display":"United Kingdom","ppb_city":"London","ppb_state":null,"ppb_state_display":null,"ppb_country":"GB","ppb_country_display":"United Kingdom"},{"name":"ROIVANT SCIENCES GMBH","contribution":"0.00","ownership_percentage":"0.00","address":"Viaduktstrasse 8 - 4051","city":"Basel","state":null,"state_display":null,"country":"CH","country_display":"Switzerland","ppb_city":"Basel","ppb_state":null,"ppb_state_display":null,"ppb_country":"CH","ppb_country_display":"Switzerland"}],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/b4d65b30-5e24-44ee-b66c-d73e0ef36468/","filing_uuid":"b4d65b30-5e24-44ee-b66c-d73e0ef36468","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2019,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/b4d65b30-5e24-44ee-b66c-d73e0ef36468/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Bryant Hall, President","dt_posted":"2019-10-21T17:53:32.110000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1300 Connecticut Avenue, NW","registrant_address_2":"Suite 600","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20036","registrant":{"id":400712135,"url":"https://lda.gov/api/v1/registrants/400712135/","house_registrant_id":null,"name":"TIBER CREEK HEALTH STRATEGIES, INC.","description":"Government Relations.","address_1":"750 9th Street NW","address_2":"Suite 501","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JONATHON JONES","contact_telephone":"+1 202-775-8116","dt_updated":"2026-07-20T13:08:01.259800-04:00"},"client":{"id":194559,"url":"https://lda.gov/api/v1/clients/194559/","client_id":214,"name":"PECK MADIGAN JONES (ON BEHALF OF ROIVANT SCIENCES, INC.)","general_description":"Biopharmaceutical drug development.","client_government_entity":false,"client_self_select":null,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-04-18"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to the development of gene therapies","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":54797,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"BRYANT","last_name":"HALL","suffix":"ii","suffix_display":"II"},"covered_position":null,"new":false}],"government_entities":[{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Issues related to the development of gene therapies; treatment of Parkinson's disease","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":54797,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"BRYANT","last_name":"HALL","suffix":"ii","suffix_display":"II"},"covered_position":null,"new":false}],"government_entities":[{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[{"name":"ROIVANT SCIENCES LTD.","contribution":"0.00","ownership_percentage":"0.00","address":"Clarendon House - 2 Church Street","city":"Hamilton","state":null,"state_display":null,"country":"BM","country_display":"Bermuda","ppb_city":"Hamilton","ppb_state":null,"ppb_state_display":null,"ppb_country":"BM","ppb_country_display":"Bermuda"},{"name":"ROIVANT SCIENCES HOLDINGS LTD.","contribution":"0.00","ownership_percentage":"0.00","address":"11-12 St. Jame's Square, Suite 1, 3rd Floor","city":"London","state":null,"state_display":null,"country":"GB","country_display":"United Kingdom","ppb_city":"London","ppb_state":null,"ppb_state_display":null,"ppb_country":"GB","ppb_country_display":"United Kingdom"}],"affiliated_organizations":[{"name":"ROIVANT SCIENCES, INC.","url":null,"address_1":"320 West 37th Street","address_2":null,"address_3":null,"address_4":null,"city":"New York","state":"NY","state_display":"New York","zip":"10018","country":"US","country_display":"United States of America","ppb_city":null,"ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America"}]},{"url":"https://lda.gov/api/v1/filings/f2bc5a60-bada-42aa-ad73-5018f07b8ca9/","filing_uuid":"f2bc5a60-bada-42aa-ad73-5018f07b8ca9","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2019,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/f2bc5a60-bada-42aa-ad73-5018f07b8ca9/print/","filing_document_content_type":"text/html","income":"70000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Jeffrey J. Peck, Partner","dt_posted":"2019-10-21T16:47:22.513000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1300 CONNECTICUT AVENUE, NW","registrant_address_2":"Suite 600","registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20036","registrant":{"id":20744,"url":"https://lda.gov/api/v1/registrants/20744/","house_registrant_id":31587,"name":"TIBER CREEK GROUP","description":"Government Relations.","address_1":"750 9th Street NW","address_2":"Suite 501","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"GRACE BAUM","contact_telephone":"+1 202-381-6896","dt_updated":"2026-07-20T13:07:00.819992-04:00"},"client":{"id":127265,"url":"https://lda.gov/api/v1/clients/127265/","client_id":1006168,"name":"ROIVANT SCIENCES, INC.","general_description":"Biopharmaceutical drug development.","client_government_entity":false,"client_self_select":null,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-04-18"},"lobbying_activities":[{"general_issue_code":"TEC","general_issue_code_display":"Telecommunications","description":"Issues pertaining to telemedicine and implementation of Special Registration rule. Implementation of SUPPORT for Patients and Communities Act (Public Law No: 115-271).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":65014,"prefix":null,"prefix_display":null,"first_name":"JAMES","nickname":null,"middle_name":null,"last_name":"HEIMBACH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":53494,"prefix":null,"prefix_display":null,"first_name":"ANDREW","nickname":null,"middle_name":null,"last_name":"MCKECHNIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":26450,"prefix":null,"prefix_display":null,"first_name":"JONATHON","nickname":null,"middle_name":null,"last_name":"JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":58384,"prefix":"mr","prefix_display":"MR.","first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"SHAPIRO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":47178,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":"MICHAEL","last_name":"GONZALEZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61401,"prefix":null,"prefix_display":null,"first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69921,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"LEFFINGWELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Treatment of diabetes, gene therapies and treatment of Parkinsons disease, telemedicine","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":65014,"prefix":null,"prefix_display":null,"first_name":"JAMES","nickname":null,"middle_name":null,"last_name":"HEIMBACH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":53494,"prefix":null,"prefix_display":null,"first_name":"ANDREW","nickname":null,"middle_name":null,"last_name":"MCKECHNIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":26450,"prefix":null,"prefix_display":null,"first_name":"JONATHON","nickname":null,"middle_name":null,"last_name":"JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":47178,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":"MICHAEL","last_name":"GONZALEZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":58384,"prefix":"mr","prefix_display":"MR.","first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"SHAPIRO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61401,"prefix":null,"prefix_display":null,"first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69921,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"LEFFINGWELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Treatment of diabetes, gene therapies, treatment of Parkinsons disease, HR 2740 the Labor-HHS Appropriations Bill","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":69921,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"LEFFINGWELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Treatment of diabetes, gene therapies and treatment of Parkinsons disease","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":65014,"prefix":null,"prefix_display":null,"first_name":"JAMES","nickname":null,"middle_name":null,"last_name":"HEIMBACH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":53494,"prefix":null,"prefix_display":null,"first_name":"ANDREW","nickname":null,"middle_name":null,"last_name":"MCKECHNIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":26450,"prefix":null,"prefix_display":null,"first_name":"JONATHON","nickname":null,"middle_name":null,"last_name":"JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":47178,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":"MICHAEL","last_name":"GONZALEZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":58384,"prefix":"mr","prefix_display":"MR.","first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"SHAPIRO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61401,"prefix":null,"prefix_display":null,"first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69921,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"LEFFINGWELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[{"name":"ROIVANT SCIENCES LTD.","contribution":"0.00","ownership_percentage":"0.00","address":"Clarendon House - 2 Church Street","city":"Hamilton","state":null,"state_display":null,"country":"BM","country_display":"Bermuda","ppb_city":"Hamilton","ppb_state":null,"ppb_state_display":null,"ppb_country":"BM","ppb_country_display":"Bermuda"},{"name":"ROIVANT SCIENCES HOLDINGS LTD.","contribution":"0.00","ownership_percentage":"0.00","address":"11-12 St. Jame's Square, Suite 1, 3rd Floor","city":"London","state":null,"state_display":null,"country":"GB","country_display":"United Kingdom","ppb_city":"London","ppb_state":null,"ppb_state_display":null,"ppb_country":"GB","ppb_country_display":"United Kingdom"}],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/622ba84a-98d4-4c60-9ca1-2eb94fcd5c22/","filing_uuid":"622ba84a-98d4-4c60-9ca1-2eb94fcd5c22","filing_type":"2A","filing_type_display":"2nd Quarter - Amendment","filing_year":2019,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/622ba84a-98d4-4c60-9ca1-2eb94fcd5c22/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Bryant Hall, President","dt_posted":"2019-07-26T15:55:09.757000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1300 Connecticut Avenue, NW","registrant_address_2":"Suite 600","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20036","registrant":{"id":400712135,"url":"https://lda.gov/api/v1/registrants/400712135/","house_registrant_id":null,"name":"TIBER CREEK HEALTH STRATEGIES, INC.","description":"Government Relations.","address_1":"750 9th Street NW","address_2":"Suite 501","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JONATHON JONES","contact_telephone":"+1 202-775-8116","dt_updated":"2026-07-20T13:08:01.259800-04:00"},"client":{"id":194559,"url":"https://lda.gov/api/v1/clients/194559/","client_id":214,"name":"PECK MADIGAN JONES (ON BEHALF OF ROIVANT SCIENCES, INC.)","general_description":"Biopharmaceutical drug development.","client_government_entity":false,"client_self_select":null,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-04-18"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to the development of gene therapies; treatment of Parkinson's disease","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":54797,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"BRYANT","last_name":"HALL","suffix":"ii","suffix_display":"II"},"covered_position":null,"new":false}],"government_entities":[{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Issues related to the development of gene therapies; treatment of Parkinson's disease","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":54797,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"BRYANT","last_name":"HALL","suffix":"ii","suffix_display":"II"},"covered_position":null,"new":false}],"government_entities":[{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/20a5ecfa-3a75-44fe-9312-762be8844bc7/","filing_uuid":"20a5ecfa-3a75-44fe-9312-762be8844bc7","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2019,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/20a5ecfa-3a75-44fe-9312-762be8844bc7/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Bryant Hall, President","dt_posted":"2019-07-22T16:53:21.993000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1300 Connecticut Avenue, NW","registrant_address_2":"Suite 600","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20036","registrant":{"id":400712135,"url":"https://lda.gov/api/v1/registrants/400712135/","house_registrant_id":null,"name":"TIBER CREEK HEALTH STRATEGIES, INC.","description":"Government Relations.","address_1":"750 9th Street NW","address_2":"Suite 501","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JONATHON JONES","contact_telephone":"+1 202-775-8116","dt_updated":"2026-07-20T13:08:01.259800-04:00"},"client":{"id":194559,"url":"https://lda.gov/api/v1/clients/194559/","client_id":214,"name":"PECK MADIGAN JONES (ON BEHALF OF ROIVANT SCIENCES, INC.)","general_description":"Biopharmaceutical drug development.","client_government_entity":false,"client_self_select":null,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-04-18"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Issues related to drug development; Treatment of Parkinson's","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":54797,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"BRYANT","last_name":"HALL","suffix":"ii","suffix_display":"II"},"covered_position":null,"new":false}],"government_entities":[{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to drug development; Treatment of Parkinson's","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":54797,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"BRYANT","last_name":"HALL","suffix":"ii","suffix_display":"II"},"covered_position":null,"new":false}],"government_entities":[{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/94c8648b-c61a-405a-ac89-4641406bc069/","filing_uuid":"94c8648b-c61a-405a-ac89-4641406bc069","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2019,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/94c8648b-c61a-405a-ac89-4641406bc069/print/","filing_document_content_type":"text/html","income":"70000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Jeffrey J. Peck, Partner","dt_posted":"2019-07-22T15:41:33.750000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1300 CONNECTICUT AVENUE, NW","registrant_address_2":"Suite 600","registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20036","registrant":{"id":20744,"url":"https://lda.gov/api/v1/registrants/20744/","house_registrant_id":31587,"name":"TIBER CREEK GROUP","description":"Government Relations.","address_1":"750 9th Street NW","address_2":"Suite 501","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"GRACE BAUM","contact_telephone":"+1 202-381-6896","dt_updated":"2026-07-20T13:07:00.819992-04:00"},"client":{"id":127265,"url":"https://lda.gov/api/v1/clients/127265/","client_id":1006168,"name":"ROIVANT SCIENCES, INC.","general_description":"Biopharmaceutical drug development.","client_government_entity":false,"client_self_select":null,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-04-18"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues pertaining to womens health and treatment of endometriosis; Treatment of diabetes; Treatment of rare diseases; Gene therapies and treatment of Parkinsons disease; Treatment of Sickle Cell","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":65014,"prefix":null,"prefix_display":null,"first_name":"JAMES","nickname":null,"middle_name":null,"last_name":"HEIMBACH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":53494,"prefix":null,"prefix_display":null,"first_name":"ANDREW","nickname":null,"middle_name":null,"last_name":"MCKECHNIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":26450,"prefix":null,"prefix_display":null,"first_name":"JONATHON","nickname":null,"middle_name":null,"last_name":"JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":47178,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":"MICHAEL","last_name":"GONZALEZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":58384,"prefix":"mr","prefix_display":"MR.","first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"SHAPIRO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61401,"prefix":null,"prefix_display":null,"first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69921,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"LEFFINGWELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Issues pertaining to womens health and treatment of endometriosis; Treatment of diabetes; Treatment of rare diseases; Gene therapies and treatment of Parkinsons disease; Treatment of Sickle Cell. HR 2740, the Labor-HHS Appropriations Bill","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":69921,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"LEFFINGWELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TEC","general_issue_code_display":"Telecommunications","description":"Issues pertaining to telemedicine and implementation of Special Registration rule. Implementation of SUPPORT for Patients and Communities Act (Public Law No: 115-271).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":65014,"prefix":null,"prefix_display":null,"first_name":"JAMES","nickname":null,"middle_name":null,"last_name":"HEIMBACH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":53494,"prefix":null,"prefix_display":null,"first_name":"ANDREW","nickname":null,"middle_name":null,"last_name":"MCKECHNIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":26450,"prefix":null,"prefix_display":null,"first_name":"JONATHON","nickname":null,"middle_name":null,"last_name":"JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":58384,"prefix":"mr","prefix_display":"MR.","first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"SHAPIRO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":47178,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":"MICHAEL","last_name":"GONZALEZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61401,"prefix":null,"prefix_display":null,"first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69921,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"LEFFINGWELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Issues pertaining to womens health and treatment of endometriosis; Treatment of diabetes; Treatment of rare diseases; Gene therapies and treatment of Parkinsons disease; Treatment of Sickle Cell","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":65014,"prefix":null,"prefix_display":null,"first_name":"JAMES","nickname":null,"middle_name":null,"last_name":"HEIMBACH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":53494,"prefix":null,"prefix_display":null,"first_name":"ANDREW","nickname":null,"middle_name":null,"last_name":"MCKECHNIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":26450,"prefix":null,"prefix_display":null,"first_name":"JONATHON","nickname":null,"middle_name":null,"last_name":"JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":47178,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":"MICHAEL","last_name":"GONZALEZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":58384,"prefix":"mr","prefix_display":"MR.","first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"SHAPIRO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61401,"prefix":null,"prefix_display":null,"first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69921,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"LEFFINGWELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[{"name":"ROIVANT SCIENCES LTD.","contribution":"0.00","ownership_percentage":"0.00","address":"Clarendon House - 2 Church Street","city":"Hamilton","state":null,"state_display":null,"country":"BM","country_display":"Bermuda","ppb_city":"Hamilton","ppb_state":null,"ppb_state_display":null,"ppb_country":"BM","ppb_country_display":"Bermuda"},{"name":"ROIVANT SCIENCES HOLDINGS LTD.","contribution":"0.00","ownership_percentage":"0.00","address":"11-12 St. Jame's Square, Suite 1, 3rd Floor","city":"London","state":null,"state_display":null,"country":"GB","country_display":"United Kingdom","ppb_city":"London","ppb_state":null,"ppb_state_display":null,"ppb_country":"GB","ppb_country_display":"United Kingdom"}],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/4be26ae9-8e36-4200-a9d3-c7ad7fea50c2/","filing_uuid":"4be26ae9-8e36-4200-a9d3-c7ad7fea50c2","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2019,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/4be26ae9-8e36-4200-a9d3-c7ad7fea50c2/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Bryant Hall, President","dt_posted":"2019-04-22T17:27:50.423000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1300 Connecticut Avenue, NW","registrant_address_2":"Suite 600","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20036","registrant":{"id":400712135,"url":"https://lda.gov/api/v1/registrants/400712135/","house_registrant_id":null,"name":"TIBER CREEK HEALTH STRATEGIES, INC.","description":"Government Relations.","address_1":"750 9th Street NW","address_2":"Suite 501","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JONATHON JONES","contact_telephone":"+1 202-775-8116","dt_updated":"2026-07-20T13:08:01.259800-04:00"},"client":{"id":194559,"url":"https://lda.gov/api/v1/clients/194559/","client_id":214,"name":"PECK MADIGAN JONES (ON BEHALF OF ROIVANT SCIENCES, INC.)","general_description":"Biopharmaceutical drug development.","client_government_entity":false,"client_self_select":null,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-04-18"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to drug development; Treatment of rare diseases","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":54797,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"BRYANT","last_name":"HALL","suffix":"ii","suffix_display":"II"},"covered_position":null,"new":false}],"government_entities":[{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Issues related to drug development; Treatment of rare diseases","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":54797,"prefix":"mr","prefix_display":"MR.","first_name":"JAMES","nickname":null,"middle_name":"BRYANT","last_name":"HALL","suffix":"ii","suffix_display":"II"},"covered_position":null,"new":false}],"government_entities":[{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[{"name":"ROIVANT SCIENCES LTD.","contribution":"0.00","ownership_percentage":"0.00","address":"Clarendon House - 2 Church Street","city":"Hamilton","state":null,"state_display":null,"country":"BM","country_display":"Bermuda","ppb_city":"Hamilton","ppb_state":null,"ppb_state_display":null,"ppb_country":"BM","ppb_country_display":"Bermuda"},{"name":"ROIVANT SCIENCES HOLDINGS LTD.","contribution":"0.00","ownership_percentage":"0.00","address":"20-22 Bedford Row","city":"London","state":null,"state_display":null,"country":"GB","country_display":"United Kingdom","ppb_city":"London","ppb_state":null,"ppb_state_display":null,"ppb_country":"GB","ppb_country_display":"United Kingdom"}],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/d8434543-8ce3-48d5-a450-ed13db992e74/","filing_uuid":"d8434543-8ce3-48d5-a450-ed13db992e74","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2019,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/d8434543-8ce3-48d5-a450-ed13db992e74/print/","filing_document_content_type":"text/html","income":"70000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Jeffrey J. Peck, Partner","dt_posted":"2019-04-22T15:34:59.667000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1300 CONNECTICUT AVENUE, NW","registrant_address_2":"Suite 600","registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20036","registrant":{"id":20744,"url":"https://lda.gov/api/v1/registrants/20744/","house_registrant_id":31587,"name":"TIBER CREEK GROUP","description":"Government Relations.","address_1":"750 9th Street NW","address_2":"Suite 501","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"GRACE BAUM","contact_telephone":"+1 202-381-6896","dt_updated":"2026-07-20T13:07:00.819992-04:00"},"client":{"id":127265,"url":"https://lda.gov/api/v1/clients/127265/","client_id":1006168,"name":"ROIVANT SCIENCES, INC.","general_description":"Biopharmaceutical drug development.","client_government_entity":false,"client_self_select":null,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-04-18"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues pertaining to womens health and treatment of endometriosis; Treatment of diabetes; Treatment of rare diseases; Gene therapies and treatment of Parkinsons disease; Treatment of Sickle Cell","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":65014,"prefix":null,"prefix_display":null,"first_name":"JAMES","nickname":null,"middle_name":null,"last_name":"HEIMBACH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":53494,"prefix":null,"prefix_display":null,"first_name":"ANDREW","nickname":null,"middle_name":null,"last_name":"MCKECHNIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":26450,"prefix":null,"prefix_display":null,"first_name":"JONATHON","nickname":null,"middle_name":null,"last_name":"JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":47178,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":"MICHAEL","last_name":"GONZALEZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":58384,"prefix":"mr","prefix_display":"MR.","first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"SHAPIRO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61401,"prefix":null,"prefix_display":null,"first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69921,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"LEFFINGWELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Issues pertaining to womens health and treatment of endometriosis; Treatment of diabetes; Treatment of rare diseases; Gene therapies and treatment of Parkinsons disease; Treatment of Sickle Cell","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":69921,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"LEFFINGWELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Issues pertaining to womens health and treatment of endometriosis; Treatment of diabetes; Treatment of rare diseases; Gene therapies and treatment of Parkinsons disease; Treatment of Sickle Cell","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":65014,"prefix":null,"prefix_display":null,"first_name":"JAMES","nickname":null,"middle_name":null,"last_name":"HEIMBACH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":53494,"prefix":null,"prefix_display":null,"first_name":"ANDREW","nickname":null,"middle_name":null,"last_name":"MCKECHNIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":26450,"prefix":null,"prefix_display":null,"first_name":"JONATHON","nickname":null,"middle_name":null,"last_name":"JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":47178,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":"MICHAEL","last_name":"GONZALEZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":58384,"prefix":"mr","prefix_display":"MR.","first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"SHAPIRO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61401,"prefix":null,"prefix_display":null,"first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69921,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"LEFFINGWELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[{"name":"ROIVANT SCIENCES LTD.","contribution":"0.00","ownership_percentage":"0.00","address":"Clarendon House - 2 Church Street","city":"Hamilton","state":null,"state_display":null,"country":"BM","country_display":"Bermuda","ppb_city":"Hamilton","ppb_state":null,"ppb_state_display":null,"ppb_country":"BM","ppb_country_display":"Bermuda"},{"name":"ROIVANT SCIENCES HOLDINGS LTD.","contribution":"0.00","ownership_percentage":"0.00","address":"11-12 St. Jamess Square, Suite 1, 3rd Floor","city":"London","state":null,"state_display":null,"country":"GB","country_display":"United Kingdom","ppb_city":"London","ppb_state":null,"ppb_state_display":null,"ppb_country":"GB","ppb_country_display":"United Kingdom"}],"affiliated_organizations":[]}]}